Novo Nordisk A/S (NYSE:NVO) Shares Sold by RFG Advisory LLC

RFG Advisory LLC lowered its stake in Novo Nordisk A/S (NYSE:NVO) by 40.9% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 12,024 shares of the company’s stock after selling 8,304 shares during the quarter. RFG Advisory LLC’s holdings in Novo Nordisk A/S were worth $1,034,000 as of its most recent filing with the SEC.

Several other hedge funds have also modified their holdings of NVO. International Assets Investment Management LLC raised its stake in shares of Novo Nordisk A/S by 10,608.4% during the third quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock valued at $215,942,000 after purchasing an additional 1,796,635 shares during the period. Mediolanum International Funds Ltd purchased a new stake in Novo Nordisk A/S during the 3rd quarter worth $98,765,000. Wellington Management Group LLP acquired a new position in Novo Nordisk A/S in the 3rd quarter worth $42,017,000. Sanctuary Advisors LLC purchased a new position in Novo Nordisk A/S in the 2nd quarter valued at about $41,646,000. Finally, World Investment Advisors LLC grew its stake in shares of Novo Nordisk A/S by 2,655.9% during the third quarter. World Investment Advisors LLC now owns 280,409 shares of the company’s stock valued at $33,388,000 after acquiring an additional 270,234 shares in the last quarter. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Novo Nordisk A/S Stock Performance

Novo Nordisk A/S stock opened at $87.94 on Friday. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. Novo Nordisk A/S has a 12 month low of $78.17 and a 12 month high of $148.15. The company has a fifty day moving average price of $95.35 and a two-hundred day moving average price of $115.17. The company has a market cap of $394.65 billion, a PE ratio of 28.46, a P/E/G ratio of 0.90 and a beta of 0.45.

Analysts Set New Price Targets

NVO has been the subject of a number of analyst reports. Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. UBS Group upgraded Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. BMO Capital Markets dropped their price target on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research note on Monday, December 23rd. StockNews.com downgraded shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. Finally, BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $145.25.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.